SCHEMBL7944676

SCHEMBL7944676

Cc1c(C(=O)Nc2cccc(CNc3cccnc3N)c2)oc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.57
RAB9A P51151 9/20 0.56
TSHR P16473 2/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
NPC1 O15118 7/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 2/20 0.56
RXFP1 Q9HBX9 1/20 0.56
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
ATM Q13315 1/20 0.52
GAA P10253 1/20 0.51
MAP3K5 Q99683 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940970 0.91 BACE1 (0.56) BACE1RAB9ATSHRHPGDHSD17B10
SCHEMBL7944478 0.90 BACE1 (0.55) BACE1RAB9ATSHRHPGDHSD17B10
SCHEMBL7944489 0.89 RAB9A (0.59) BACE1RAB9ATSHRHPGDHSD17B10
SCHEMBL7939891 0.89 BACE1 (0.56) BACE1RAB9ATSHRHPGDHSD17B10
SCHEMBL7939896 0.89 BACE1 (0.54) BACE1RAB9ATSHRHPGDHSD17B10
SCHEMBL7944680 0.88 BACE1 (0.59) BACE1RAB9ANPC1RXFP1ATM
SCHEMBL7945003 0.87 RAB9A (0.56) RAB9ATSHRHPGDHSD17B10NPC1
SCHEMBL7933478 0.85 RAB9A (0.53) RAB9ATSHRHPGDHSD17B10NPC1
SCHEMBL7945232 0.83 BACE1 (0.53) BACE1RAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL7941663 0.83 BACE1 (0.58) BACE1RAB9ATSHRHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885RAB9A 1287/4885TSHR 4179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.